Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin - Ocular Therapeutix

Drug Profile

Ciclosporin - Ocular Therapeutix

Alternative Names: Ciclosporin ophthalmic insert - Ocular Therapeutix; Cyclosporine intracanalicular insert - Ocular Therapeutix; OTX-CSI; OTX-CSI intracanalicular insert; Sustained release ciclosporin intracanalicular hydrogel insert - Ocular Therapeutix

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ocular Therapeutix
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Dry eyes

Most Recent Events

  • 31 Dec 2024 Suspended - Phase-II for Dry eyes in USA (Ophthalmic)
  • 31 Mar 2023 Ocular Therapeutix plans a pivotal trial for Dry eyes (Opthalmic, Implant) in Q2 of 2023 (Ocular Therapeutix pipeline, March 2023)
  • 22 Feb 2022 Ocular Therapeutix completes phase II portion of phase I/II trial in Dry eyes in USA (Ophthalmic) (NCT04362670)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top